Original Article
Association of E-cadherin Expression with Histopathological Grades and Clinical Stages of Laryngeal Squamous Cell Carcinoma
*Tayeb M,1Mimi SA,2 Kamal MS,3 Snigdha SS4
- *Dr. Mohammad Tayeb, MD (Pathology), Assistant Professor, Department of Pathology, Jahurul Islam Medical College. tmohammad75@yahoo.com
- Professor Dr. Shamim Akhter Mimi, M. Phil (Pathology), Professor and Head, Department of Pathology, Sylhet MAG Osmani Medical College.
- Mohammad Shah Kamal, FCPS (ENT), Associate Professor, Department of Otorhinology & Head-Neck Surgery, Sylhet MAG Osmani Medical College.
- Shyla Sharmin Snigdha, MD (Pathology),Assistant professor, Department of Pathology, Zainul Haque Sikder Women’s Medical College.
*For correspondence
Abstract
Background: E-cadherin gene plays an important role in the carcinogenesis of laryngeal squamous cell carcinoma (LSCC). This study aimed to evaluate the immunohistochemical expression of E-cadherin in different grades and clinical stages of LSCC and to determine the association of E-cadherin with clinical stages and histopathological grades.
Methods: This cross-sectional study was conducted in the Department of Pathology, Sylhet MAG Osmani Medical College, from March 2021 to January 2023. Immunohistochemistry was performed in 50 histopathologically diagnosed cases of LSCC using a commercially available anti-E-cadherin antibody. The total score of immunoreaction was calculated by multiplying the expression score and intensity score.
Results: The mean age of the LSCC patients was 62.8 years, and 66% were male. Grade I is the most frequent histopathological grade (48%), followed by grade II (42%) and grade III (10%). The most frequent clinical T stage was T3 (56%), and the N stage was N2 (58.06%). E-cadherin expression was positive in 72% of cases; the rest, 28%, showed reduced expression. A significant association was found between E-cadherin expression with histopathological grades (p=0.007) and clinical N stage (p=0.009) but not significant with clinical T stage (p=0.502), anatomic site (P=0.132), and the habit of smoking (0.276).
Conclusion: LSCC patients with reduced E-cadherin expression are at the risk of high-grade carcinoma and nodal metastasis. So, the expression of E-cadherin in pre-treatment biopsy samples can be utilized as one of the prognostic factors and advocated to anti-E-cadherin targeted therapy in LSCC.
[Journal of Histopathology and Cytopathology, 2025 Jan; 9 (1):3-9]
Keywords: E-cadherin, Expression, Immunohistochemistry, laryngeal squamous cell carcinoma.
DOI: https://www.doi.org/10.69950/jhc2025v9i1s2